Risk of bleeding with concomitant use of oral anticoagulants and aspirin: A systematic review and meta-analysis
- PMID: 38263263
- DOI: 10.1093/ajhp/zxae010
Risk of bleeding with concomitant use of oral anticoagulants and aspirin: A systematic review and meta-analysis
Abstract
Purpose: Oral anticoagulants (OACs) and aspirin can trigger bleeding events when used alone or in combination. The purpose of this study was to compare the risk of any type of bleeding in individuals exposed to a combination of OAC and aspirin with the risk in those taking an OAC or aspirin alone.
Methods: MEDLINE and Web of Science were queried in January 2021 for eligible articles. Studies were included if they were either randomized controlled trials (RCTs) or observational studies and evaluated the number of any bleeding events in two groups, one with exposure to both OAC and aspirin and one with exposure to OAC alone or aspirin alone. Pooled odds ratios were calculated using a random-effects model.
Results: Forty-two studies were included. In an analysis of 15 RCTs and 19 observational studies evaluating OAC plus aspirin versus OAC alone, a significant difference in the risk of bleeding was observed in the combination groups, with an odds ratio [OR] of, 1.36 (95% CI, 1.15-1.59) for RCTs and an OR of 1.42 (95% CI-, 1.09-1.87) for observational studies. When OAC plus aspirin was compared to aspirin alone, a higher rate of bleeding was found in the combination group (OR, 2.36; 95%CI, 1.91-2.92) in the analysis of 15 RCTs, but no significant difference was found among 10 observational studies (OR, 1.93; 95% Cl, 0.99-3.75).
Conclusion: The risk of any type of bleeding was significantly increased among patients taking aspirin plus OAC compared to those taking OAC alone in both RCTs and observational studies. Evaluation of RCTs comparing OAC plus aspirin to aspirin alone suggests increased bleeding risk as well.
Keywords: anticoagulants; bleeding risk; drug interaction; gastrointestinal bleeding; salicylates; warfarin.
© American Society of Health-System Pharmacists 2024. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Similar articles
-
Meta-analysis of randomized controlled trials and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention.Am J Cardiol. 2015 May 1;115(9):1185-93. doi: 10.1016/j.amjcard.2015.02.003. Epub 2015 Feb 12. Am J Cardiol. 2015. PMID: 25799015 Review.
-
Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials.Arch Intern Med. 2007 Jan 22;167(2):117-24. doi: 10.1001/archinte.167.2.117. Arch Intern Med. 2007. PMID: 17242311 Review.
-
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.JACC Cardiovasc Interv. 2019 Dec 9;12(23):2331-2341. doi: 10.1016/j.jcin.2019.08.039. JACC Cardiovasc Interv. 2019. PMID: 31806214 Clinical Trial.
-
The Cost of Breaking Even: a Perspective on the Net Clinical Impact of Adding Aspirin to Antithrombotic Therapies in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.Cardiovasc Drugs Ther. 2024 Jun;38(3):605-619. doi: 10.1007/s10557-022-07367-3. Epub 2022 Jul 13. Cardiovasc Drugs Ther. 2024. PMID: 35829979 Review.
-
Dual versus triple therapy in patients on oral anticoagulants and undergoing coronary stent implantation: A systematic review and meta-analysis.Int J Cardiol. 2018 Dec 15;273:80-87. doi: 10.1016/j.ijcard.2018.08.019. Epub 2018 Aug 9. Int J Cardiol. 2018. PMID: 30115419
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
